azaguanine has been researched along with Leukemia--Myeloid--Acute* in 8 studies
1 trial(s) available for azaguanine and Leukemia--Myeloid--Acute
| Article | Year |
|---|---|
[AML-6 and AML-7 studies on the treatment of acute myelocytic leukemia. Cyclic alternating chemotherapy during remission, and induction of remission and survival of elderly patients].
Twenty-five institutions are participating in the AML-6-trial designed to improve remission incidence and to delay the time of relapse. Therefore, an intensive cyclic therapy is employed early after achievement of remission using either the same drugs of the induction regimen or rotating combinations of alternative drugs, e.g. AMSA, 5-AZA and HD-araC. So far, 266 patients entered the trial. The overall C.R. rate is 71%. 58 patients are randomized to 'maintenance' arm I, 54 to arm II, 79/112 patients are still being studied. Toxicity was in 7% and 3% respectively a reason to interrupt the study during induction or 'maintenance'. Since the intensity of modern protocols for remission induction of AML presents a major problem in elderly patients due to toxicity, and since most studies indicate low remission rates with an increasing death rate in this age group, the AML-7-study was initiated to prospectively compare survival and quality of life of two different therapeutic strategies: immediate intensive remission induction versus supportive care, 'wait and see' policy, and palliative cytoreduction with hydroxyurea and ara C when necessary. During the first 8 months after activating this study, 27 patients entered, 13 were randomized to branch I, and 14 to branch II. Topics: Adult; Age Factors; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azaguanine; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Middle Aged; Vincristine | 1985 |
7 other study(ies) available for azaguanine and Leukemia--Myeloid--Acute
| Article | Year |
|---|---|
[Expression of seven oncogenes in HL-60-AR cells and their changes after chemically induced differentiation].
Topics: Azaguanine; Cell Differentiation; Cell Line; Dimethyl Sulfoxide; Drug Resistance; Gene Expression Regulation; Humans; Hypoxanthine Phosphoribosyltransferase; Leukemia, Myeloid, Acute; Oncogenes; Tretinoin | 1987 |
Guanine analog-induced differentiation of human promyelocytic leukemia cells and changes in queuine modification of tRNA.
Treatment of hypoxanthine-guanine phosphoribosyltransferase (HGPRT)-deficient human promyelocytic leukemia (HL-60) cells with 6-thioguanine results in growth inhibition and cell differentiation. 6-Thioguanine is a substrate for the tRNA modification enzyme tRNA-guanine ribosyltransferase, which normally catalyzes the exchange of queuine for guanine in position 1 of the anticodon of tRNAs for asparagine, aspartic acid, histidine, and tyrosine. During the early stages of HGPRT-deficient HL-60 cell differentiation induced by 6-thioguanine, there was a transient decrease in the queuine content of tRNA, and changes in the isoacceptor profiles of tRNA(His) indicate that 6-thioguanine was incorporated into the tRNA in place of queuine. Reversing this structural change in the tRNA anticodon by addition of excess exogenous queuine reversed the 6-thioguanine-induced growth inhibition and differentiation. Similar results were obtained when 8-azaguanine (another inhibitor of queuine modification of tRNA that can be incorporated into the anticodon) replaced 6-thioguanine as the inducing agent. The data suggest a primary role for the change in queuine modification of tRNA in mediating the differentiation of HGPRT-deficient HL-60 cells induced by guanine analogs. Topics: Antibodies, Monoclonal; Antigens, Differentiation; Azaguanine; Cell Differentiation; Guanine; Humans; Hypoxanthine Phosphoribosyltransferase; Leukemia, Myeloid, Acute; Nitroblue Tetrazolium; RNA Processing, Post-Transcriptional; RNA, Transfer; Thioguanine; Tumor Cells, Cultured | 1987 |
[Establishment of human promyelocytic leukemia cell mutant (HL-60-AR) with characteristics of resistance to 8-AG and deficiency in HGPRT].
Topics: Azaguanine; Cell Line; Drug Resistance; Genetic Markers; Humans; Hypoxanthine Phosphoribosyltransferase; Leukemia, Myeloid, Acute; Methylnitronitrosoguanidine; Mutation | 1986 |
[Potency of induced differentiation in vitro of a human promyelocytic leukemia cell mutant (HL-60-AR) with characteristics of resistance to 8-AG and deficiency in HGPRT].
Topics: Azaguanine; Cell Differentiation; Cell Line; Dimethyl Sulfoxide; Drug Resistance; Humans; Hypoxanthine Phosphoribosyltransferase; Hypoxanthines; Leukemia, Myeloid, Acute; Tretinoin | 1986 |
[Antimetabolites in the treatment of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. II].
Topics: Antimetabolites; Azacitidine; Azaguanine; Azauridine; Cell Membrane Permeability; Cytarabine; DNA, Neoplasm; Fluorouracil; Humans; Immunity, Cellular; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Purines; Pyrimidines | 1974 |
[Antimetabolites in the therapy of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. I].
Topics: Aminopterin; Antimetabolites; Azaguanine; Cytarabine; DNA, Neoplasm; Humans; Immunity, Cellular; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Purines; Quinazolines; RNA, Neoplasm | 1974 |
[Characterization of a hybrid cell line, "human leukemia-Chinese hamster"].
Topics: Animals; Azaguanine; Cell Line; Cricetinae; Dactinomycin; Fibroblasts; Fluorescent Antibody Technique; Genotype; Humans; Hybrid Cells; Karyotyping; Leukemia, Myeloid, Acute; Mitosis; Parainfluenza Virus 1, Human; Selection, Genetic | 1973 |